Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) is a subtype of B-cell lymphoma that arises from the mucosa-associated lymphoid tissue. It is characterized by the infiltration of malignant B-cells in various extranodal sites. In recent years, significant progress has been made in understanding the pathogenesis and developing effective diagnostics and therapies for MALT lymphoma. Our company, a leading player in the field of biomedical research and drug development, is committed to advancing the understanding and therapy development of MALT lymphoma.
Overview of MALT
Mucosa-associated lymphoid tissue lymphoma (MALT), also known as MALT lymphoma or MALToma, occurs in about 1.53 males and 1.61 females per 100,000 individuals, respectively. It is a slow-growing type of lymphoma that primarily affects the mucosa-associated lymphoid tissue. This tissue is responsible for immune surveillance and defense against pathogens at various mucosal sites throughout the body. MALT lymphoma most commonly occurs in the stomach, where it is associated with chronic infection by the bacterium Helicobacter pylori (H. pylori). In addition to H. pylori, bacterial and viral infections have also been implicated in the development of MALT lymphomas in other parts of the body.
Fig.1 IHC results of gastric MALT lymphoma. (Pham, Nhu Hiep, et al., 2024)Targets of MALT Therapy Development
- Tumor Microenvironment
The tumor microenvironment, such as immune cells and stromal cells, as well as cytokines and chemokines, plays a critical role in supporting the growth and survival of MALT lymphoma cells.
- B-cell Signaling Pathways
Aberrant activation of B-cell signaling pathways, such as the NF-κB and PI3K-Akt pathways, has been implicated in the pathogenesis of MALT lymphoma.
Types of MALT Therapy Development
- H. pylori Eradication
For early-stage MALT lymphoma associated with H. pylori infection, the first-line therapy involves eradicating the bacterial infection. This approach has shown significant success in achieving remission and preventing disease progression.
- Monoclonal Antibodies
Monoclonal Antibodies specifically designed to inhibit molecules involved in MALT lymphoma pathogenesis are being developed, such as rituximab (anti-CD20), and have shown promising results in clinical trials. These antibodies selectively target lymphoma cells, leading to their destruction by the immune system.
- Small Molecule Drugs
Small molecule drugs remain a mainstay of therapy for advanced or refractory MALT lymphoma. Combination therapies, including oral alkylating agents and purine nucleoside analogs, have demonstrated favorable outcomes in clinical studies.
- Immunotherapy
Immunotherapy approaches, such as immune checkpoint inhibitors and adoptive T-cell therapies, are being explored for MALT lymphoma. These therapies aim to harness the power of the immune system to recognize and eliminate lymphoma cells.
Our Services
Accurate and early diagnosis of MALT lymphoma is crucial for effective therapy. Our company invests in the development of advanced diagnostic tools and assays to aid in the detection, staging, and monitoring of MALT lymphoma. We collaborate with leading experts in the field to ensure the highest standards of diagnostic accuracy.
Our team of experienced researchers and scientists work diligently to develop innovative therapies for MALT lymphoma. We employ cutting-edge technologies and methodologies to identify novel targets, design therapy development solutions and rare disease models, and conduct preclinical to evaluate their pharmacokinetics and safety.
MALT Therapy Development Platforms
Animal Models of MALT
- Gastric MALT lymphoma models
- Non-gastric MALT lymphoma models
We have the expertise to make processes more efficient, thereby reducing costs and time. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Pham, Nhu Hiep, et al. "Helicobacter pylori-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma in a Girl." Case Reports in Oncology 17.1 (2024): 256-263.
- Filip, Petruta Violeta, et al. "MALT lymphoma: epidemiology, clinical diagnosis and treatment." Journal of medicine and life 11.3 (2018): 187.
- Uhl, Barbara, et al. "Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas." World Journal of Gastrointestinal Oncology 14.1 (2022): 153.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.